Skip Navigation


NDT Advance Access originally published online on October 31, 2008
Nephrology Dialysis Transplantation 2009 24(4):1097-1103; doi:10.1093/ndt/gfn605
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/4/1097    most recent
gfn605v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Domhan, S.
Right arrow Articles by Abdollahi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domhan, S.
Right arrow Articles by Abdollahi, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Immunosuppressive therapy and post-transplant malignancy

Sophie Domhan1,2,3, Martin Zeier2 and Amir Abdollahi1,3

1 Department of Medicine, Center of Cancer Systems Biology, Caritas St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA 2 Department of Nephrology, University of Heidelberg Medical School 3 Department of Radiation Oncology, German Cancer Research Center (DKFZ) and University of Heidelberg Medical School, 69120 Heidelberg, Germany

Correspondence and offprint requests to: Sophie Domhan, Department of Medicine, Center of Cancer Systems Biology, Caritas St. Elizabeth's Medical Center, Tufts University, 736 Cambridge Street, CBR1, Boston, MA 02135, USA. Tel: +1-617-779-6569; Fax: +1-617-562-7142; E-mail: Sophie.Domhan@Tufts.edu

Keywords: cancer; immunosuppressive drugs; transplantation

The first 150 words of the full text of this article appear below.



   Introduction
 
Organ transplantation is a well-established method for the therapy of end-stage organ failure. The emergence of novel immunosuppressive regimens has reduced the risk of rejection and extended the life expectancy of organ recipients. The long-term outcome of these patients is now challenged by life-threatening complications such as cardiovascular disease, infections and post-transplant malignancies. Malignancy is a well-recognized complication of transplantation and can manifest as de novo cancer, as a recurrence of a pre-existing malignancy or from transmission of malignancy from the donor. Recent studies show that tumour incidence increases with time after organ transplantation and is related to the intensity of immunosuppression [1,2]. Overall, a 3- to 4-fold increased incidence of cancer has been observed in transplant patients compared with age-matched controls in the general population. During immunosuppressive therapy, there is a higher frequency of some relatively rare tumours that tend to be biologically more aggressive than those . . . [Full Text of this Article]



   mTOR inhibitors
 


   Azathioprine and mycophenolic acid
 


   FTY720
 


   Calcineurin inhibitors
 


   Biological agents and small molecules
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll Cardiol IntvHome page
S. Kufner, J. Hausleiter, G. Ndrepepa, S. Schulz, O. Bruskina, R. A. Byrne, M. Fusaro, A. Kastrati, A. Schomig, J. Mehilli, et al.
Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis
J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1142 - 1148.
[Abstract] [Full Text] [PDF]